Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-15
2005-11-15
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S220000, C514S259410
Reexamination Certificate
active
06964962
ABSTRACT:
A composition comprising:(a) a pharmaceutically effective amount of reboxetine; and selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof(b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof is provided.
REFERENCES:
patent: 3505451 (1970-04-01), Burnings et al.
patent: 0 830 864 (1998-03-01), None
patent: 0 966 967 (1999-12-01), None
patent: 2 722 099 (1994-07-01), None
patent: WO 99/61014 (1999-12-01), None
Koch et al, Eur. J. Clin. Pharmacol. (56, No. 6-7, A10, 2000) (abstract).
E. Aragues, et al., “Reboxetine in Negative Symptoms of Schizophrenia”, European Psychiatry, 2000, pp 426S, Abstract Only.
G. Schutz, et al., “Reboxetine Add on Therapy to Haloperidol in The Treatment of Schizophrenia: a Preliminary Double-blind Randomized Placebo-controlled Study”, International Clinical Psychopharmacology, 2001, pp 275-278, vol. 16, No. 5.
E. Spina, et al, “No Effect of Reboxetine on Plasma Concentrations of Clozapine, Risperidone, and Their Active Metabolites”, 2001, pp675-678, vol. 23 No. 6.
Fong Wong Erik Ho
Gallen Christopher C.
Svensson Torgny
Ashbrook Charles W.
Kurlandsky David R.
Pharmacia & Upjohn Company
Spivack Phyllis G.
LandOfFree
Combinations of reboxetine and neuroleptic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinations of reboxetine and neuroleptic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinations of reboxetine and neuroleptic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467575